What's new in dry eye research today? | Sep 16, 2026

【Title】Structural and Mechanical Insights into the Extracellular Matrix of the Aging Human Lacrimal Gland for Tissue Engineering Applications

【Journal】Acta Biomater

【Authors】Felix Greese; Nina Reiter; Martin Schicht; et al.

【Summary】This study characterized the extracellular matrix composition and mechanical properties of aging human lacrimal gland tissue, finding a heterogeneous ECM dominated by collagen III and VI and an ultra-soft viscoelastic behavior with a shear modulus of 0.21 kPa. These quantitative structural and mechanical parameters provide reference characteristics of the aging lacrimal gland microenvironment and may guide the development of ECM-mimetic biomaterials and scaffolds for lacrimal gland regeneration.

【Title】Gas tamponade choice in low-to-moderate complexity primary rhegmatogenous retinal detachment: propensity-matched comparisons of SF6, C2F6 and C3F8

【Journal】Br J Ophthalmol

【Authors】Nikolaos Tzoumas; Xiaoman S Li; David Yorston; et al.

【Summary】This registry-based study compared SF6, C2F6, and C3F8 gas tamponades in primary rhegmatogenous retinal detachment repair using data from 7466 eyes for anatomical outcomes and 5734 for visual outcomes. C2F6 showed a possible anatomical advantage over SF6 and C3F8, while C2F6 and SF6 had similar postoperative visual acuity; C3F8 was associated with worse visual acuity and higher risks of cystoid macular oedema or raised intraocular pressure compared with the other gases.

【Title】A 1% glycopyrronium bromide cream for topical treatment of severe primary axillary hyperhidrosis in adolescents: safety, local tolerability, systemic exposure and efficacy from an open-label phase II study

【Journal】J Dtsch Dermatol Ges

【Authors】Rolf-Markus Szeimies; Ana Kilic; Hubert Reich; et al.

【Summary】This open-label phase II study evaluated 1% glycopyrronium bromide cream in 42 adolescents aged 12–17 years with severe primary axillary hyperhidrosis over 8 weeks, with two mild adverse drug reactions reported, including dry eye in one patient, and no serious adverse events. Sweat production, hyperhidrosis severity, and quality of life improved significantly at days 29 and 57 (all p<0.001), supporting favorable short-term safety and tolerability.